Press Release Summary:
Designed for in vivo molecular imaging applications, X-SIGHT Imaging Agents help identify molecular abnormalities at very early stage, expediting development of treatment options that could help cure disease. Once attached to molecule and injected into organism, agents travel to target and highlight region of interest. X-Sight imaging agents are non-toxic, making them safe for research studies in oncology, cardiology, diabetes, and inflammation.
Original Press Release:
Kodak Launches New Imaging Agent Product Line for Research Applications
Enables Early Disease Detection and Treatment
NEW HAVEN, Conn.---Eastman Kodak Company's Molecular Imaging Systems group announced the introduction of KODAK X-SIGHT Imaging Agents, a novel line of imaging agents for in vivo molecular imaging applications. The new product line will be shown at the 14th International Molecular Medicine Tri-Conference, beginning today in San Francisco, Calif., and running through March 2.
In vivo molecular imaging allows non-invasive measurement of biological processes within a living organism. In contrast to conventional diagnostic imaging that highlights conditions caused by disease, molecular imaging identifies molecular abnormalities that are the origin of disease at a very early stage, which can expedite the development of treatment options that could help cure that disease.
Once attached to a molecule and injected into an organism, the KODAK X-Sight imaging agents will travel to the target (such as a tumor) and highlight the region of interest. X-Sight imaging agents are non-toxic, making them safe for research studies in areas such as oncology, cardiology, diabetes, and inflammation, to name a few. They are uniquely designed to offer significant advantages over currently available agents, enabling researchers to perform pioneering research studies that could lead to a better understanding of the origin of these diseases.
This new product line leverages Kodak's 50 years of dye chemistry and nanotechnology expertise, to produce state-of-the-art nanoparticle products. X-Sight imaging agents deliver superior brightness and enhanced stability, providing researchers a versatile platform for molecular imaging. KODAK X-Sight imaging agents are available in several distinct varieties and can be adapted to a wide range of applications.
"The launch of X-Sight Imaging Agents, is a significant milestone toward offering our customers a complete solution of systems and agents to advance their research," commented Shahram Hejazi, PhD, Worldwide General Manager of Kodak's Molecular Imaging Systems division. "This introduction strengthens our leadership in the molecular imaging arena as we move forward to bridge the gap between preclinical and clinical applications."
Together with Kodak's In-Vivo Imaging Systems, the X-Sight Imaging Agent product line further expands the breadth of leading edge solutions offered from Kodak to the medical research community to accelerate life science and drug discovery research. X-Sight imaging agents are currently available for preclinical use in the United States and will be launched worldwide in March. Kodak plans to introduce additional imaging agents throughout the year.
About Kodak's Molecular Imaging Systems Group
Eastman Kodak Company's Molecular Imaging Systems group--part of Kodak's Health Group--develops and markets high performance digital imaging systems, imaging agents, film and accessories for the life science research and drug discovery/development market segments.
For more information, visit www.kodak.com/go/molecular or call 1-877-747-4357, express code 7. Outside of the United States, call 203-786-5657.